Navigation Links
New drug, Vemurafenib, doubles survival of metastatic melanoma patients
Date:3/1/2012

A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib increasing median survival from about 6 months to 15.9 months. In patients who responded, the drug stopped cancer progression for a median 6.7 months.

"For melanoma patients with a BRAF V600 mutation, this drug is a breakthrough. Not a cure, but a major breakthrough," says Karl Lewis, MD, investigator at the University of Colorado Cancer Center, associate professor at the University of Colorado School of Medicine, and one of the study's authors.

Lewis notes that until about 18 months ago, no drug existed for metastatic melanoma the most dangerous form of skin cancer that was proven to extend survival past that of patients who chose not to treat the disease. The CU Cancer Center is a leading treatment center for metastatic melanoma, and has been instrumental in enrolling patients in trials of this new category of melanoma drugs BRAF inhibitors.

The BRAF mutation is a known oncogene a gene that when mutated causes cancer. Specifically, the BRAF V600 mutation signals a cell to grow without bounds. Vemurafenib is a BRAF inhibitor. The mutation turns cancer on and Vemurafenib turns it off.

And turning off BRAF in the approximately 100,000 patients diagnosed worldwide each year with BRAF-positive metastatic melanoma more than doubles their time of survival.

"Rarely do we see results this dramatic," says Lewis. "This represents a new standard of care for patients with metastatic melanoma harboring a BRAF mutation."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Page: 1

Related medicine news :

1. DOE laboratories help develop promising new cancer fighting drug, vemurafenib
2. Mental Disorders Linked to Drug, Alcohol Abuse in U.S. Vets
3. New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients
4. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
5. Cancer Risk Doubles After Organ Transplant, Study Finds
6. Capacity to diagnose osteoporosis doubles in Armenia
7. ADHD Doubles a Childs Risk of Injury: Study
8. Bone marrow transplant survival more than doubles for young high-risk leukemia patients
9. EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
10. Sitting for long periods doubles risk of blood clots in the lungs
11. Text message support for smokers doubles quit rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... , ... Spectrum Aquatics has launched a brand new ADA pool lift, the ... the user in mind. , “Over the last two years our key customers and ... lbs lift is a necessary requirement for certain facilities with specific needs,” said Nabil ...
(Date:5/31/2016)... Clearwater, FL (PRWEB) , ... May 31, 2016 , ... ... for its innovative herbal energy pouches, on World No Tobacco Day . ... in select retail locations later on this summer. , The new flavor is ...
(Date:5/31/2016)... IL (PRWEB) , ... May 31, 2016 , ... ... multichannel marketing services firm and statement solutions provider, for the tenth ... in the May 2016 issue of Advertising Age, and SourceLink ranked eighteenth in ...
(Date:5/30/2016)... ... 30, 2016 , ... As the CDC relaxes its stance on traditional No-Nit ... keep their households lice free. , According to a May 26 article from ... kids in the classroom despite the fact that they may be harboring an infestation. ...
(Date:5/30/2016)... ... May 30, 2016 , ... Another ER facility operated by First Choice ... Legacy Drive, Plano, TX and is open 24 hours daily. , First Choice Emergency ... medical open house. The Jasper High School band entertained attendees and accepted First Choice ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... 25, 2016 MedDay, a biotechnology company ... an oral presentation entitled "High doses of biotin in progressive ... be given by Professor Ayman Tourbah , Principal Investigator ... the European Academy of Neurology (EAN) in Copenhagen, ... 3" will take place on Sunday, 29 May 2016 from ...
Breaking Medicine Technology: